



## Hepatitis E Virus and Immunology Research

Guest Editor:

**Prof. Dr. Jacques Izopet**

Laboratory of Virology –  
Federative Institute of Biology,  
Toulouse University Hospital &  
INSERM U1043/CNRS5282,  
Toulouse, France

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editor

HEV is the most common cause of acute viral hepatitis worldwide. Improvements in diagnostic algorithms based on serological and molecular tools are associated with a dramatic increase in the number of cases of HEV infection reported to public health authorities. HEV can take different transmission routes depending on the genotype. HEV-1 and HEV-2 are predominant in countries with limited resources, where they are transmitted via contaminated water, while HEV-3 and HEV-4 are predominant in the other countries, where they are transmitted from a large animal reservoir, mainly pigs. HEV-1 can result in fulminant hepatic failure and severe placental disease in pregnant women. We now know that only HEV-3 and HEV-4 can produce chronic hepatitis E in immunocompromised individuals. Furthermore, extra-hepatic manifestations such as neurological and renal manifestations are increasingly being reported. The mechanisms responsible for the variety of clinical manifestations of HEV infection remain poorly characterized. This Special Issue of Vaccines is dedicated to our current knowledge of HEV and future directions of research on HEV vaccines.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)